Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.
SUPN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for SUPN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Supernus Pharmaceuticals Inc ranked in the 75th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Supernus Pharmaceuticals Inc, consider:
Its compound free cash flow growth rate, as measured over the past 5.51 years, is 0.36% -- higher than 72.76% of stocks in our DCF forecasting set.
Supernus Pharmaceuticals Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 18.67% of tickers in our DCF set.
As a business, Supernus Pharmaceuticals Inc experienced a tax rate of about 16% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 70.53% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Supernus Pharmaceuticals Inc? See VTRS, SUWN, CI, LHCG, and UHS.
Exact Sciences saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 75 to 85. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. Exact Sciences is now considered extended and out of buy range after clearing a 139.36 buy point in a second-stage cup with handle.
ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021, at 9:10 a.m. ET, and will be available for virtual investor meetings. A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of this webcast will be available for 60 days on the Company's website after the conference.About Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. is a p...